Disc Medicine, Inc. (IRON) Dividend History

Company News

• Disc Medicine (IRON) Q2 Loss Widens 109%

  Disc Medicine reported a Q2 2025 net loss of $55.2 million, with increased research and development expenses. The company is advancing clinical trials for bitopertin and other pipeline programs targeting blood disorders, with a strong cash position of $650 million to fund operations through 2028.

  The Motley Fool
• Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

  Disc Medicine, a clinical-stage biopharmaceutical company, announced the pricing of its upsized public offering of common stock and pre-funded warrants, raising approximately $225.5 million. The company plans to use the proceeds to fund research, clinical development, and potential commercialization of its product candidates.

  GlobeNewswire Inc.
• Wall Street Breakfast: The Week Ahead

  The article discusses upcoming events and earnings reports that investors should watch, including the consumer price index report, Federal Reserve minutes,...

  Seeking Alpha

  Featured Companies: ACB AMLX APLD BIRK BLK C DAL FAST GOOG GOOGL HUM INTC JPM KMX KULR MRVL NEOG PSMT RENT SIGA STZ TLRY WFC WULF
• Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More

  Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.

  Zacks Investment Research

  Featured Companies: BMY VERV VNDA
• Top 3 Health Care Stocks You'll Regret Missing This Month

  The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) On March 27, Syros Pharmaceuticals posted weaker-than-expected fourth-quarter results. "We are ...

  Benzinga

  Featured Companies: HUM